{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T02:35:46Z","timestamp":1790562946018,"version":"4.1.0"},"reference-count":66,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"45","license":[{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,10]]},"abstract":"<jats:p>The mitogen-activated protein kinases family of genes plays a crucial role in a wide range of inflammatory responses in the human body. The MAPK family of genes includes ERK, ERK5, JNK, <jats:italic toggle=\"yes\">P<\/jats:italic>-38 mitogen-activated protein kinases. However, the correlation between MAPK family gene expression and pan-cancer prognosis, as well as the tumor microenvironment, has not been extensively studied. This study integrated multiple bioinformatics analysis methods to assess the expression and prognostic value of MAPK family genes, as well as their relationship with tumor microenvironment in patients with pan-cancer. The results showed that ERK, JNK, and <jats:italic toggle=\"yes\">P<\/jats:italic>-38 MAPK expression were found to be significantly upregulated in rectum adenocarcinoma (READ), colon adenocarcinoma\/rectum adenocarcinoma esophageal carcinoma (COADREAD), and kidney renal clear cell carcinoma (KIRC), and significantly downregulated in acute myeloid leukemia. And the results revealed good prognostic results for ERK, JNK, and <jats:italic toggle=\"yes\">P<\/jats:italic>-38 MAPK in READ, COADREAD, and KIRC. We observed significant positive correlation between MAPK family gene expression and immune scores especially dendritic cells in READ, COADREAD, and KIRC. And we observed that the expression levels of MAPK family genes were significantly correlated with the expression of immune-related genes, such as CXCL1, CXCL2, CXCL8, CXCR1, CXCR2, CTLA-4, CD80, CD86, and CD28, suggesting their important role in regulating immune infiltrates and tumor progression. Therefore, our study suggested that MAPK family gene plays an important role in regulating immune infiltrates and tumor progression.<\/jats:p>","DOI":"10.1097\/md.0000000000035829","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T19:07:06Z","timestamp":1699643226000},"page":"e35829","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["A pan-cancer analysis of the MAPK family gene and their association with prognosis, tumor microenvironment, and therapeutic targets"],"prefix":"10.1097","volume":"102","author":[{"given":"Yuan-Yuan","family":"Qin","sequence":"first","affiliation":[{"name":"School of Pharmacy, Inner Mongolia Medical University, Huhhot, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yang","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Inner Mongolia Medical University, Huhhot, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Hui","family":"Ren","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Inner Mongolia Medical University, Huhhot, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Inner Mongolia Medical University, Huhhot, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Jie","family":"Wang","sequence":"additional","affiliation":[{"name":"Medical Experimental Center, Department of Pharmacology, School of Basic Medical Sciences, Inner Mongolia Medical University, Huhhot, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Li","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Inner Mongolia Medical University, Huhhot, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Xia","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Inner Mongolia Medical University, Huhhot, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9981-3374","authenticated-orcid":false,"given":"Lei","family":"Fan","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Inner Mongolia Medical University, Huhhot, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1353\/pbm.2019.0046","article-title":"What is cancer?","volume":"62","author":"Hausman","year":"2019","journal-title":"Perspect Biol Med"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1002\/ijc.33114","article-title":"Profiling global cancer incidence and mortality by socioeconomic development.","volume":"147","author":"Lortet-Tieulent","year":"2020","journal-title":"Int J Cancer"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1172\/JCI127201","article-title":"Adipocyte and lipid metabolism in cancer drug resistance.","volume":"129","author":"Cao","year":"2019","journal-title":"J Clin Invest"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"3924400","DOI":"10.1155\/2022\/3924400","article-title":"HHLA2 used as a potential prognostic and immunological biomarker and correlated with tumor microenvironment in pan-cancer.","volume":"2022","author":"Yang","year":"2022","journal-title":"Biomed Res Int"},{"key":"R6-20250504","first-page":"3855","article-title":"Tumor microenvironment: recent advances in various cancer treatments.","volume":"22","author":"Wang","year":"2018","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/cac2.12178","article-title":"Advancing to the era of cancer immunotherapy.","volume":"41","author":"Wang","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s10147-021-01913-z","article-title":"Aging, cancer, and antitumor immunity.","volume":"27","author":"Ikeda","year":"2022","journal-title":"Int J Clin Oncol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"102019","DOI":"10.1016\/j.ctrv.2020.102019","article-title":"Review of precision cancer medicine: evolution of the treatment paradigm.","volume":"86","author":"Tsimberidou","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"eaay4014","DOI":"10.1126\/science.aay4014","article-title":"The science and medicine of human immunology.","volume":"369","author":"Pulendran","year":"2020","journal-title":"Science"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.3389\/fimmu.2018.02909","article-title":"Immunomodulation of the tumor microenvironment: turn foe into friend.","volume":"9","author":"Locy","year":"2018","journal-title":"Front Immunol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13073-022-01050-w","article-title":"Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response.","volume":"14","author":"Zhang","year":"2022","journal-title":"Genome Med"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1039\/C4CS00370E","article-title":"Cancer biomarker detection: recent achievements and challenges.","volume":"44","author":"Wu","year":"2015","journal-title":"Chem Soc Rev"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41392-022-00990-4","article-title":"High-throughput single-\u0441ell sequencing in cancer research.","volume":"7","author":"Jia","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2019.06.021","article-title":"Immune checkpoints in the tumor microenvironment.","volume":"65","author":"Toor","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00428-019-02538-4","article-title":"Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma.","volume":"474","author":"Ottaviano","year":"2019","journal-title":"Virchows Arch"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41392-021-00729-7","article-title":"Technological advances in cancer immunity: from immunogenomics to single-cell analysis and artificial intelligence.","volume":"6","author":"Xu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"R18-20250504","first-page":"1997","article-title":"ERK\/MAPK signalling pathway and tumorigenesis.","volume":"19","author":"Guo","year":"2020","journal-title":"Exp Ther Med"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.3390\/cancers13123026","article-title":"MAPK\/ERK signaling pathway in hepatocellular carcinoma.","volume":"13","author":"Moon","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/1541-7786.MCR-20-0687","article-title":"The MEK\/ERK network as a therapeutic target in human cancer.","volume":"19","author":"Barbosa","year":"2021","journal-title":"Mol Cancer Res"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1128\/MMBR.00031-10","article-title":"Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases.","volume":"75","author":"Cargnello","year":"2011","journal-title":"Microbiol Mol Biol Rev"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"106398","DOI":"10.1016\/j.phrs.2022.106398","article-title":"A renewed concept on the MAPK signaling pathway in cancers: Polyphenols as a choice of therapeutics.","volume":"184","author":"Anjum","year":"2022","journal-title":"Pharmacol Res"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"188736","DOI":"10.1016\/j.bbcan.2022.188736","article-title":"E3 ligases and deubiquitinating enzymes regulating the MAPK signaling pathway in cancers.","volume":"1877","author":"Park","year":"2022","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.3390\/ijms21031102","article-title":"Targeting MAPK signaling in cancer: mechanisms of drug resistance and sensitivity.","volume":"21","author":"Lee","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.3390\/cancers14153735","article-title":"Pan-cancer analysis reveals SH3TC2 as an oncogene for colorectal cancer and promotes tumorigenesis via the MAPK pathway.","volume":"14","author":"Huang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","article-title":"Inflammation and tumor progression: signaling pathways and targeted intervention.","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.3390\/ijms21072531","article-title":"Current insights into combination therapies with MAPK inhibitors and immune checkpoint blockade.","volume":"21","author":"Shin","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","article-title":"TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells.","volume":"77","author":"Li","year":"2017","journal-title":"Cancer Res"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles.","volume":"12","author":"Newman","year":"2015","journal-title":"Nat Methods"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data.","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat Commun"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-019-0638-6","article-title":"Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data.","volume":"11","author":"Finotello","year":"2019","journal-title":"Genome Med"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ccell.2015.03.007","article-title":"The journey from discoveries in fundamental immunology to cancer immunotherapy.","volume":"27","author":"Miller","year":"2015","journal-title":"Cancer Cell"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s40425-018-0458-z","article-title":"Oncolytic virus immunotherapy: future prospects for oncology.","volume":"6","author":"Raja","year":"2018","journal-title":"J ImmunoTher Cancer"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1126\/science.aar7112","article-title":"Personalized vaccines for cancer immunotherapy.","volume":"359","author":"Sahin","year":"2018","journal-title":"Science"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines.","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41571-021-00588-9","article-title":"Harnessing cytokines and chemokines for cancer therapy.","volume":"19","author":"Propper","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13045-019-0701-1","article-title":"Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation.","volume":"12","author":"Kaeuferle","year":"2019","journal-title":"J Hematol Oncol"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3389\/fimmu.2020.00784","article-title":"The tumor microenvironment in the response to immune checkpoint blockade therapies.","volume":"11","author":"Petitprez","year":"2020","journal-title":"Front Immunol"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nri3495","article-title":"Mitogen-activated protein kinases in innate immunity.","volume":"13","author":"Arthur","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"10260","DOI":"10.3390\/ijms221910260","article-title":"Growth factors, PI3K\/AKT\/mTOR and MAPK signaling pathways in colorectal cancer pathogenesis: where are we now?","volume":"22","author":"Stefani","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R41-20250504","doi-asserted-by":"crossref","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The tumor microenvironment.","volume":"30","author":"Anderson","year":"2020","journal-title":"Curr Biol"},{"key":"R42-20250504","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41392-020-00449-4","article-title":"Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy.","volume":"6","author":"Tang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"R43-20250504","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/hep.31092","article-title":"Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma.","volume":"72","author":"Job","year":"2020","journal-title":"Hepatology"},{"key":"R44-20250504","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/s41423-021-00655-2","article-title":"Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment.","volume":"18","author":"Liu","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"R45-20250504","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejca.2020.11.014","article-title":"The immune landscape of neuroblastoma: challenges and opportunities for novel therapeutic strategies in pediatric oncology.","volume":"144","author":"Wienke","year":"2021","journal-title":"Eur J Cancer"},{"key":"R46-20250504","doi-asserted-by":"crossref","first-page":"680442","DOI":"10.3389\/fimmu.2021.680442","article-title":"The broad immunomodulatory effects of IL-7 and its application in vaccines.","volume":"12","author":"Huang","year":"2021","journal-title":"Front Immunol"},{"key":"R47-20250504","doi-asserted-by":"crossref","first-page":"768813","DOI":"10.3389\/fimmu.2021.768813","article-title":"Neutrophil-derived IL-17 promotes ventilator-induced lung injury via p38 MAPK\/MCP-1 pathway activation.","volume":"12","author":"Liao","year":"2021","journal-title":"Front Immunol"},{"key":"R48-20250504","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors.","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"R49-20250504","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade.","volume":"184","author":"Morad","year":"2021","journal-title":"Cell"},{"key":"R50-20250504","doi-asserted-by":"crossref","first-page":"eabm9409","DOI":"10.1126\/sciimmunol.abm9409","article-title":"Human dendritic cells in cancer.","volume":"7","author":"Kvedaraite","year":"2022","journal-title":"Sci Immunol"},{"key":"R51-20250504","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy.","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"R52-20250504","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: a moving target in immunotherapy.","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood"},{"key":"R53-20250504","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions.","volume":"21","author":"Yi","year":"2022","journal-title":"Mol Cancer"},{"key":"R54-20250504","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.tips.2019.11.003","article-title":"Preserving the CTLA-4 checkpoint for safer and more effective cancer immunotherapy.","volume":"41","author":"Liu","year":"2020","journal-title":"Trends Pharmacol Sci"},{"key":"R55-20250504","doi-asserted-by":"crossref","first-page":"e2023739118","DOI":"10.1073\/pnas.2023739118","article-title":"Treg-expressed CTLA-4 depletes CD80\/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells.","volume":"118","author":"Tekguc","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"R56-20250504","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","article-title":"A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains.","volume":"18","author":"Cappell","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"R57-20250504","doi-asserted-by":"crossref","first-page":"e003131","DOI":"10.1136\/jitc-2021-003131","article-title":"CCR1 and CCR5 mediate cancer-induced myelopoiesis and differentiation of myeloid cells in the tumor.","volume":"10","author":"Zilio","year":"2022","journal-title":"J ImmunoTher Cancer"},{"key":"R58-20250504","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.tcb.2019.07.002","article-title":"Regulatory mechanisms of inhibitory immune checkpoint receptors expression.","volume":"29","author":"Curdy","year":"2019","journal-title":"Trends Cell Biol"},{"key":"R59-20250504","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.immuni.2021.04.004","article-title":"MDSC: markers, development, states, and unaddressed complexity.","volume":"54","author":"Hegde","year":"2021","journal-title":"Immunity"},{"key":"R60-20250504","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1158\/2159-8290.CD-21-0764","article-title":"Myeloid-derived suppressor cells: a propitious road to clinic.","volume":"11","author":"Grover","year":"2021","journal-title":"Cancer Discov"},{"key":"R61-20250504","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cytogfr.2016.08.002","article-title":"The CXCL8-CXCR1\/2 pathways in cancer.","volume":"31","author":"Liu","year":"2016","journal-title":"Cytokine Growth Factor Rev"},{"key":"R62-20250504","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","article-title":"Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer.","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"R63-20250504","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.7150\/thno.15625","article-title":"Role of the CXCL8-CXCR1\/2 axis in cancer and inflammatory diseases.","volume":"7","author":"Ha","year":"2017","journal-title":"Theranostics"},{"key":"R64-20250504","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3390\/molecules27010137","article-title":"Roles of the CXCL8-CXCR1\/2 axis in the tumor microenvironment and immunotherapy.","volume":"27","author":"Han","year":"2021","journal-title":"Molecules"},{"key":"R65-20250504","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.3390\/ijms23042168","article-title":"CXCR2 Receptor: regulation of expression, signal transduction, and involvement in cancer.","volume":"23","author":"Korbecki","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R66-20250504","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1093\/carcin\/bgad009","article-title":"SSH1 promotes progression of intrahepatic cholangiocarcinoma via p38 MAPK-CXCL8 axis.","volume":"44","author":"Chen","year":"2023","journal-title":"Carcinogenesis"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035829","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:29:49Z","timestamp":1746325789000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,10]]},"references-count":66,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000035829","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,10]]}}}